Home › Kanser sa Pantog › Ohio › Columbus
Pag-aaral pangklinika para sa Kanser sa Pantog sa Columbus, OH
19 pag-aaral para sa Kanser sa Pantog ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Columbus (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Nagre-recruitPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- at 11 pa
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Nagre-recruitPhase 2
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- Doctors Hospital, Columbus
- at 1 pa
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- at 8 pa
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Nagre-recruitPhase 1
- The Ohio State University (OSU), Columbus
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Nagre-recruitPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Nagre-recruitPhase 3
- Ohio State University Comprehensive Cancer Center, Columbus
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
Nagre-recruitObservasyonal na pag-aaral
- The Ohio State University, Columbus
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Nagre-recruitPhase 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Nagre-recruitPhase 3
- Ohio State University Comprehensive Cancer Center, Columbus
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Nagre-recruitPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Nagre-recruitPhase 1
- Ohio State University, Columbus
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Nagre-recruitPhase 2
- Ohio State University, Columbus
- Central Ohio Urology Group (US Urology Partners), Gahanna · 7 mi ang layo
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Nagre-recruitPhase 1/2
- Central Ohio Urology Group, Gahanna · 7 mi ang layo
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Nagre-recruitPhase 2/3
- The James Outpatient Care West Campus, Columbus
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Nagre-recruitPhase 2
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Nagre-recruitPhase 2
- Ohio State University Hospital, Columbus
- Ohio State University, Columbus
- OSU Wexner Medical Center & James Cancer Hospital, Columbus
- at 2 pa
Blue Light Cystoscopy With Cysview® Registry
Nagre-recruitObservasyonal na pag-aaral
- Ohio State University Wexner Medical Center, Columbus
- Ohio State University, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Columbus
Pag-aaral para sa Kanser sa Pantog sa ibang lungsod
- New York City, NY36 pag-aaral
- Nashville, TN31 pag-aaral
- Houston, TX31 pag-aaral
- Dallas, TX27 pag-aaral
- Boston, MA26 pag-aaral
- Washington, DC26 pag-aaral
- Los Angeles, CA25 pag-aaral
- Baltimore, MD24 pag-aaral
- Philadelphia, PA23 pag-aaral
- Edison, NJ23 pag-aaral
- St. Louis, MO22 pag-aaral
- Chicago, IL21 pag-aaral
Iba pang pag-aaral sa Columbus
- Non-Small Cell Lung Cancer57 pag-aaral
- Kanser (lahat ng uri)40 pag-aaral
- Kanser sa Suso39 pag-aaral
- Kanser sa Ovary39 pag-aaral
- Kanser sa Baga36 pag-aaral
- Acute Myeloid Leukemia34 pag-aaral
- Chronic Lymphocytic Leukemia29 pag-aaral
- Metastatic Cancer25 pag-aaral
- Multiple Myeloma25 pag-aaral
- Kanser sa Prostate25 pag-aaral
- Kanser ng Endometrium24 pag-aaral
- Colorectal Cancer24 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.